SS
OVID icon

SBI Securities’s Ovid Therapeutics OVID Stock Holding History

SBI Securities’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$238 Sell
107
-82
-43% -$147 ﹤0.01% 3158
2025
Q4 		$308 Sell
189
-236
-56% -$364 ﹤0.01% 3059
2025
Q3 		$553 Sell
425
-459
-52% -$398 ﹤0.01% 2931
2025
Q2 		$292 Hold
884
– – ﹤0.01% 3188
2025
Q1 		$276 Buy
884
+800
+952% +$492 ﹤0.01% 3105
2024
Q4 		$78 Buy
+84
New +$94 ﹤0.01% 3530

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SBI Securities's OVID Position: Q1 2026 in Review

SBI Securities reduced its Ovid Therapeutics (OVID) stake by 43% in Q1 2026, selling an estimated $147 and leaving 107 shares worth $238. The position accounts for ﹤0.01% of the portfolio, ranked #3158.

SBI Securities first reported a position in OVID in Q4 2024 and has held it in 6 quarters since. The position peaked at $553 in Q3 2025. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • SBI Securities held 107 shares of Ovid Therapeutics worth $238 as of Q1 2026.
  • SBI Securities sold 82 Ovid Therapeutics shares in Q1 2026, an estimated $147.
  • Ovid Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #3158 holding.
  • SBI Securities first reported a position in Ovid Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Ovid Therapeutics position peaked at $553 in Q3 2025.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.